East China Pharmaceutical: wholly-owned subsidiary Injection HDM2024 has been approved for clinical trials.

East China Medicine announced that on March 25, 2026, its wholly-owned subsidiary Zhongmei East China received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the injection HDM2024 clinical trial application, with the indication for advanced solid tumors. This drug is a type 1 biopharmaceutical developed by Zhongmei East China, and preclinical studies have shown it to have strong anti-tumor activity, good drug properties, and safety. In addition, the phase I clinical trial application for the indication of late-stage solid tumors was approved by the U.S. FDA in March 2026. Drug research and development involve uncertainties, but have no significant impact on the company's recent performance.